HSBC Holdings
TCRX icon

HSBC Holdings’s TScan Therapeutics TCRX Stock Holding History

HSBC Holdings’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.8K Hold
24,574
– – ﹤0.01% 2893
2026
Q1 		$24.4K Hold
24,574
– – ﹤0.01% 2850
2025
Q4 		$24.8K Hold
24,574
– – ﹤0.01% 2896
2025
Q3 		$43.9K Sell
24,574
-5,927
-19% -$10.5K ﹤0.01% 2650
2025
Q2 		$44.2K Sell
30,501
-4,541
-13% -$6.56K ﹤0.01% 2942
2025
Q1 		$49.4K Buy
+35,042
New +$75.8K ﹤0.01% 2904

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

HSBC Holdings's TCRX Position: Q2 2026 in Review

HSBC Holdings held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 24,574 shares worth $23.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2893.

HSBC Holdings first reported a position in TCRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $49.4K in Q1 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • HSBC Holdings held 24,574 shares of TScan Therapeutics worth $23.8K as of Q2 2026.
  • HSBC Holdings left its TScan Therapeutics share count unchanged in Q2 2026.
  • TScan Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2893 holding.
  • HSBC Holdings first reported a position in TScan Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • HSBC Holdings's TScan Therapeutics position peaked at $49.4K in Q1 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.